Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial

European Urology Oncology(2023)

引用 0|浏览7
暂无评分
摘要
Adrenal metastases could be an independent negative prognostic factor for response to anti-PD-1 therapy and survival in patients with metastatic renal cell carcinoma.
更多
查看译文
关键词
Renal cell carcinoma,Nivolumab,Immunotherapy,Glandular metastases,GETUG-AFU-26 NIVOREN trial,Adrenal metastases,Pancreatic metastases
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要